April 5th 2021
Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.
March 4th 2021
Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.
February 16th 2021
During a recent OncLive Peer Exchange®, a panel of experts in kidney cancer from the United States and France convened to discuss several important immunotherapy studies presented during the ESMO Virtual Congress 2020, as well as several others that are under way and expected to report out over the next few years.
February 5th 2021
Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.
January 12th 2021
As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.
December 4th 2020
In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.
November 3rd 2020
A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.
October 9th 2020
An increased understanding of the biologic intricacies of acute myeloid leukemia has led to the identification of more than 100 driver mutations associated with the disease, opening the door for targeted therapies with clinically meaningful outcomes for patients who are not candidates for intensive chemo-therapy regimens.
September 16th 2020
A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.
September 1st 2020
During an OncLive Peer Exchange®, a panel of orthopedic experts provided a comprehensive overview of these tumors, including their epidemiology and differential diagnosis, optimal clinical workup, and the role of surgical management.